The multiple dimensions of airways disease: Targeting treatment to clinical phenotypes

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 2, 2011, Pages 72-78

  Shirtcliffe, Philippa ^a,b   Weatherall, Mark ^b,c   Travers, Justin ^a,b   Beasley, Richard ^a,b  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

Author keywords

airways disease; asthma; COPD; phenotypes

Indexed keywords

CLARITHROMYCIN; CORTICOSTEROID; HISTONE DEACETYLASE; INTERLEUKIN 5; NITRIC OXIDE; THEOPHYLLINE;

AIRWAY OBSTRUCTION; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; ATOPY; CHRONIC BRONCHITIS; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; GENETIC RISK; HUMAN; HYPERCAPNIA; LOW DRUG DOSE; LUNG BIOPSY; LUNG EMPHYSEMA; MILD PERSISTENT ASTHMA; MODERATE PERSISTENT ASTHMA; NONEOSINOPHILIC ASTHMA; ONSET AGE; PHENOTYPE; PROGNOSIS; QUALITY OF LIFE; RISK FACTOR; SPUTUM ANALYSIS; TH2 CELL; TREATMENT RESPONSE;

ASTHMA; CLUSTER ANALYSIS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INDIVIDUALIZED MEDICINE; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 79951670027     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328341f181     Document Type: Article

References (50)

1. Editorial. A plea to abandon asthma as a disease concept. Lancet 2006; 368:705.
2. Beasley R, Weatherall M, Travers J, Shirtcliffe P. Time to define the disorders that make up the syndrome of COPD. Lancet 2009; 374:670-672.
3. Wardlaw AJ, Silverman M, Siva R, et al. Multidimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy 2005; 35:1254-1262.
4. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804-813. (Pubitemid 44279058)
5. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-224.
6. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:532-555. (Pubitemid 47403272)
7. Global initiative for asthma: Global Strategy for Asthma Management and Prevention (GINA). Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; 2002. Report No. 02-3659.
8. Anonymous. Terminology, definitions, and classification of chronic pulmonary emphysema and related conditions. A report of the conclusions of the Ciba guest symposium. Thorax 1959; 14:286-299.
9. Snider G. Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology. Am Rev Respir Dis 1989; 140:S3-S8. (Pubitemid 19231329)
10. American Thoracic Society. Standards for diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:s77-s121.
11. Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124:474-481. (Pubitemid 37000122)
12. Viegi G, Matteelli G, Angino A, et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest 2004; 126:1093-1101. (Pubitemid 39391237)
13. Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008; 63:761-767.
14. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58:659-664. (Pubitemid 36976273)
15. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133:814-819. (Pubitemid 16116509)
16. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126:59-65. (Pubitemid 38943118)
17. Vonk JM, Jongepier H, Panhuysen CI, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 2003; 58:322-327. (Pubitemid 36411418)
18. Makita H, Nasuhara Y, Nagai K, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007; 62:932-937. (Pubitemid 350084489)
19. Siddiqui S, Brightling C. Magic bullets: the new goal for asthma. Am J Respir Crit Care Med 2009; 180:383-384.
20. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372:1107-1119.
21. Cowan JC, Cowan JO, Palmay R, et al. Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 2010; 65:384-390.
22. Woodruff PG, Modrek B, Choy DF, et al. T-helper Type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388-395.
23. Celli BR, Roger S. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. Proc Am Thorac Soc 2006; 3:461-465. (Pubitemid 44285511)
24. Laperre T, Snoeck-Stroband J, Gosman M, et al. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:499-504. (Pubitemid 39209130)
25. Pavord ID, Shaw DE, Gibson PG, Taylor DR. Inflammometry to assess airway diseases. Lancet 2008; 372:1017-1019.
26. Weatherall M, Shirtcliffe P, Travers J, Beasley R. Use of cluster analysis to define COPD phenotypes. Eur Respir J 2010; 36:472-474.
27. Weatherall M, Travers J, Shirtcliffe PM, et al. Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009; 34:812-818.
28. Travers J, Marsh S, Caldwell B, et al. External validity of randomized controlled trials in COPD. Respir Med 2007; 101:1313-1320. (Pubitemid 46667661)
29. Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 2007; 62:219-223.
30. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010; 181:315-323.
31. Burgel P-R, Paillasseur J-L, Caillaud D, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analysis. Eur Respir J 2010; 36:531-539.
32. Han MK, Agusti A, Calverley PM, et al. COPD phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604.
33. Rosi E, Ronchi M, Grazzini M, et al. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J Allergy Clin Immunol 1999; 103:232-237. (Pubitemid 29095827)
34. Roy K, Smith J, Kolsum U, et al. COPD phenotype description using principal components analysis. Respir Res 2009; 10:41.
35. Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and noneosinophilic asthma. Thorax 2007; 62:1043-1049. (Pubitemid 350206195)
36. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-1721. (Pubitemid 35447900)
37. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-2173.
38. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008; 372:1065-1072.
39. Pedersen S, OByrne PM. Exhaled nitric oxide in guideline-based asthma management. Lancet 2008; 372:1015-1017.
40. Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-993.
41. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
42. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177:148-155.
43. Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57:226-230. (Pubitemid 34214408)
44. Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168:1308-1311. (Pubitemid 37487324)
45. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25:552-563. (Pubitemid 40331188)
46. Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175:783-790. (Pubitemid 46631789)
47. Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 2009; 33:1010-1017.
48. Dummer JF, Epton MJ, Cowan JO, et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med 2009; 180:846-852.
49. Antus B, Barta I, Horvath I, Csiszer E. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology 2010; 15:472-477.
50. Brightling C, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000; 356:1480-1485.